Structure (C5b0f981 45c3 4e15 B712 984b4a4f6a57 01)
Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6281
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6281). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 02)
The given text describes a graph showing the proportion of patients experiencing relapse over time after the start of treatment with either a placebo or duloxetine. The graph uses a Kaplan-Meier estimator method to plot the data. The x-axis shows the time from randomization to relapse in days, while the y-axis shows the proportion of patients experiencing relapse. The graph indicates that treatment with duloxetine resulted in a lower proportion of patients experiencing relapse compared to treatment with a placebo over the given time frame.*
Figure 2 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 03)
This is a graph showing the proportion of patients with relapse over time from randomization to relapse (measured in days) for a placebo and a drug called Duloxetine. The graph uses the Kaplan-Meier estimator method. There are no other details available in the given text.*
Figure 1 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 04)
Figure 2 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 05)
Fig 5 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 06)
The text provides a chart showing the percentage of patients improved based on the level of pain improvement from the baseline. The chart includes data for patients taking Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and a placebo. The chart displays ten different levels of pain improvement, ranging from greater than 0% improvement to 100% improvement.*
Fig 6 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 07)
This table shows the percentage of patients who experienced improvement in pain from baseline after receiving Duloxetine at different doses and a placebo. The table also shows the percentage improvement in pain for each group.*
Figure 8 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 08)
This is a graph showing the percentage of patients who experienced an improvement in pain from baseline after being treated with placebo or Duloxetine 60/120 mg once daily. The x-axis represents the percentage of improvement in pain, while the y-axis represents the number of patients. However, there isn't enough information to determine the exact percentage of patients improved for Duloxetine compared to the Placebo group.*
Figure 9 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 09)
The text provides a chart showing the percentage of patients improved with Duloxetine 60 mg versus a Placebo, without any specific context of a medical treatment or ailment. It also presents a graph showing the percentage improvement in pain from a baseline. Therefore, it seems to be a statistical analysis of the effectiveness of a drug in reducing pain.*
Figure 10 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 10)
Label Image (Lbl500906281)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
